Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Renub Research | PRODUCT CODE: 1815017

Cover Image

PUBLISHER: Renub Research | PRODUCT CODE: 1815017

United States Artificial Intelligence in Diagnostics Market Report by Component, Application, End Use, States and Company Analysis, 2025-2033

PUBLISHED:
PAGES: 200 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 2990
PDF (5 User License + Excel)
USD 3490
PDF (Corporate License)
USD 3990

Add to Cart

United States Artificial Intelligence in Diagnostics Market Size and Forecast

United States Artificial Intelligence in Diagnostics Market is expected to reach US$ 1,837.00 million by 2033 from US$ 424.41 million in 2024, with a CAGR of 17.68% from 2025 to 2033. The growing need for precision medicine, sophisticated imaging analytics, and AI-powered decision support across healthcare systems is expected to drive the US market for artificial intelligence in diagnostics.

United States Artificial Intelligence in Diagnostics Industry Overview

By improving diagnostic speed, accuracy, and efficiency, artificial intelligence (AI) in the diagnostics sector in the United States is rapidly growing and revolutionizing healthcare. Clinical procedures are rapidly using AI-powered diagnostic technologies to help doctors diagnose complicated illnesses, interpret imaging images, and analyze massive datasets. In fields like radiology, pathology, and cancer, where prompt and precise identification is essential to enhancing patient outcomes, these technologies have a particularly significant influence. The use of AI diagnostics in hospitals, clinics, and specialized healthcare facilities across the country is advancing due to the growing burden of chronic diseases, the growing need for tailored therapy, and the complexity of healthcare data.

The U.S. FDA authorized the sale of Prenosis, Inc.'s Sepsis ImmunoScore through the De Novo pathway, for example, in April 2024. It's a software as a medical device (AI SaMD) that uses artificial intelligence to improve the diagnosis and prognosis of early sepsis. In response to the persistent diagnostic difficulties this complicated illness has presented in the American healthcare system, the FDA has authorized the first marketing of an AI-based diagnostic tool for sepsis.

Innovation in technology continues to be crucial to the expansion of this business. Improvements in cloud computing, natural language processing, and machine learning algorithms are propelling advancements in diagnostic systems, facilitating quicker and more accurate clinical decision-making. AI-enabled imaging systems can now detect anomalies including cancers, fractures, and cardiovascular risks with greater precision, which lowers diagnostic errors and speeds up treatment planning. AI diagnostics usage is being further accelerated by integration with telemedicine platforms and electronic health records (EHRs), which results in smooth patient care experiences. To speed up the creation of new products and the approval of existing ones, both established and up-and-coming businesses are making significant investments in research and development as well as partnerships with healthcare organizations.

Regulatory scrutiny, data privacy issues, and high implementation costs are some of the industry's other difficulties. Smaller practices and rural centers encounter obstacles because of cost and technical know-how, even while hospitals and other advanced healthcare institutions are embracing AI-powered solutions at an accelerating rate. Fostering wider use requires ensuring regulatory compliance, preserving patient trust, and ensuring transparency in AI decision-making. The general picture is still optimistic in spite of these obstacles. AI diagnostics are anticipated to become a crucial component of U.S. healthcare delivery with ongoing innovation, encouraging healthcare investments, and an increasing focus on precision medicine. This will allow for prompt, patient-centered, and data-driven solutions.

Key Factors Driving the United States Artificial Intelligence in Diagnostics Market Growth

Rising Demand for Early and Accurate Disease Detection

The growing emphasis on early and precise disease detection is a major driver of AI diagnostics adoption in the United States. Healthcare providers face increasing pressure to diagnose complex conditions such as cancer, cardiovascular disease, and neurological disorders at earlier stages, when treatment outcomes are most favorable. AI-powered diagnostic systems excel in analyzing medical images, pathology slides, and genomic data with high speed and accuracy, helping physicians detect subtle patterns that might be missed by human observation. These technologies are reducing diagnostic errors, enhancing clinical confidence, and supporting better patient outcomes. With the aging population and growing prevalence of chronic illnesses, demand for accurate, data-driven diagnostic tools is rising. AI systems are increasingly viewed as essential partners to healthcare professionals, shaping a more efficient diagnostic landscape.

Advancements in AI Algorithms and Imaging Technologies

Rapid advancements in AI algorithms and imaging technologies are driving growth in the U.S. AI diagnostics market. Machine learning and deep learning models are continuously evolving, enabling diagnostic systems to process large, complex datasets with greater precision. Modern AI imaging platforms are improving the accuracy of detecting abnormalities in radiology, cardiology, and oncology, significantly reducing false positives and negatives. Integration with digital imaging systems such as MRI, CT scans, and ultrasound devices allows seamless application in clinical workflows. Additionally, advancements in cloud computing and edge technologies support real-time data processing, facilitating faster diagnostic results. These innovations are aligning with the growing demand for precision medicine, improving diagnostic accuracy and personalized treatment planning. As technology matures, its role in transforming diagnostic practices continues to strengthen.

Increasing Integration with Digital Health and Telemedicine

The integration of AI diagnostics with digital health and telemedicine platforms is a critical growth driver in the United States. The rise of remote care models has amplified the need for accurate, accessible diagnostic solutions that can be delivered virtually. AI-powered diagnostic tools, integrated with electronic health records (EHRs), cloud-based systems, and telehealth platforms, enable healthcare providers to analyze patient data remotely and make timely clinical decisions. This integration supports continuity of care, particularly for patients in rural or underserved areas. It also enhances collaboration among healthcare professionals by allowing easy data sharing and real-time consultation. With the growing adoption of telehealth services, AI diagnostics are becoming essential tools in delivering accessible, patient-centered care, ensuring their role in the future of U.S. healthcare delivery.

Challenges in the United States Artificial Intelligence in Diagnostics Market

Regulatory and Compliance Barriers

Regulatory compliance represents one of the most significant challenges in the U.S. AI diagnostics market. AI-powered tools, particularly those involving patient data and medical decision-making, must meet strict approval standards set by agencies such as the FDA. These processes often require extensive clinical validation and evidence of reliability, prolonging product development timelines. The dynamic nature of AI algorithms, which evolve with continuous learning, adds complexity to regulatory approval, as frameworks are not always aligned with rapidly advancing technologies. Additionally, ensuring algorithm transparency and explainability remains a concern, as physicians and patients must trust AI-driven decisions. Striking a balance between innovation and compliance is crucial for manufacturers. Without clear regulatory pathways, adoption may slow, despite the potential benefits AI brings to diagnostics and patient outcomes.

Data Privacy and High Implementation Costs

Data privacy and high implementation costs present additional challenges for AI diagnostics adoption in the United States. AI systems rely on large volumes of sensitive patient data, raising concerns about security, consent, and compliance with regulations such as HIPAA. Healthcare institutions must invest heavily in secure infrastructures to protect patient information, which can be costly and resource-intensive. Additionally, implementing AI diagnostic tools often requires significant capital investment in hardware, software, and staff training, creating barriers for smaller practices and rural healthcare providers. While larger hospitals may absorb these costs, uneven access to AI technologies can create disparities in healthcare delivery. Addressing data security risks and offering cost-effective solutions will be critical to ensuring broader adoption and equitable access across the U.S. healthcare system.

United States Artificial Intelligence in Diagnostics Market Overview by States

Regional growth in the U.S. AI diagnostics market is strongest in California, Texas, New York, and Florida, supported by advanced healthcare infrastructure, leading research centers, and growing adoption of AI-driven diagnostic technologies across diverse medical fields. The following provides a market overview by States:

California Artificial Intelligence in Diagnostics Market

California's world-class healthcare system, robust innovation ecosystem, and concentration of tech businesses make it a prominent location for artificial intelligence in diagnostics. AI-powered diagnostic technologies are being used more and more by hospitals and clinics around the state to improve the precision and effectiveness of pathology, genomic analysis, and medical imaging. The development and integration of cutting-edge diagnostic tools is being accelerated by California's robust academic institutions and partnerships between healthcare providers and AI firms. AI diagnoses are becoming more and more popular thanks to the state's emphasis on telemedicine and digital health, especially in major cities like San Diego, Los Angeles, and San Francisco. With its unique combination of innovation, cutting-edge healthcare delivery, and patient demand for precision medicine, California is a key player in determining the direction of the US AI diagnostics market.

Texas Artificial Intelligence in Diagnostics Market

Due in large part to its diversified population and growing healthcare infrastructure, Texas is becoming a major market for artificial intelligence in diagnostics. AI-enabled diagnostic technologies are being used by major medical centers in Austin, Dallas, and Houston in an effort to improve clinical outcomes and expedite patient treatment. AI is being used more quickly in radiology, pathology, and cancer thanks to the state's expanding research ecosystem, which includes partnerships between academic institutions and healthcare organizations. Enhancing healthcare accessibility is another priority for Texas, where telemedicine systems are incorporating AI diagnosis to provide care in underserved and rural areas. Texas is positioned as a key growth driver in the national AI diagnostics market due to its cutting-edge healthcare facilities, research activities, and desire for easily accessible diagnostics.

New York Artificial Intelligence in Diagnostics Market

New York's sophisticated healthcare systems, dense population, and robust research environment make it a major market for AI in diagnostics. AI-powered diagnostic technologies are being used by top hospitals and academic medical institutes to increase the precision of complex disease detection, especially in the fields of neurology, cardiology, and oncology. To improve processes and provide more effective patient care, the state's healthcare providers are utilizing AI integration with telemedicine systems and electronic health records. AI-enabled diagnostics help meet the high demand for individualized medicine created by New York's diverse population. New York is at the forefront of incorporating AI into clinical practice, bolstering its position as a significant contributor to the U.S. AI diagnostics market by emphasizing innovation, collaboration, and accessibility.

Florida Artificial Intelligence in Diagnostics Market

Florida's huge senior population and high need for early disease detection technologies are driving the state's steady expansion in the U.S. AI diagnostics sector. AI-powered solutions are being used by hospitals, clinics, and outpatient centers around the state to support cardiology, oncology, and chronic illness management diagnostics. In Florida, where it improves access to diagnostics for patients in both urban and rural locations, the integration of AI with telemedicine platforms has a particularly significant impact. The usage of AI diagnostics in routine clinical processes is increasing as a result of the state's expanding healthcare investments and embrace of digital health technologies. Florida continues to expand as a key regional market that supports the expansion of AI diagnostics across the country with its emphasis on patient-centered treatment and early intervention.

Market Segmentations

Component

  • Software
  • Services
  • Hardware

Application

  • Neurology
  • Radiology
  • Chest & Lung
  • Oncology
  • Cardiology
  • Pathology
  • Others

End Use

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Imaging Centers
  • Other End Users

States

  • California
  • Texas
  • New York
  • Florida
  • Illinois
  • Pennsylvania
  • Ohio
  • Georgia
  • New Jersey
  • Washington
  • North Carolina
  • Massachusetts
  • Virginia
  • Michigan
  • Maryland
  • Colorado
  • Tennessee
  • Indiana
  • Arizona
  • Minnesota
  • Wisconsin
  • Missouri
  • Connecticut
  • South Carolina
  • Oregon
  • Louisiana
  • Alabama
  • Kentucky
  • Rest of United States

All the Key players have been covered

  • Overviews
  • Key Person
  • Recent Developments
  • SWOT Analysis
  • Revenue Analysis

Company Analysis:

  • Siemens Healthineers
  • Riverain Technologies
  • Vuno, Inc.
  • Aidoc
  • Neural Analytics
  • Imagen Technologies
  • GE Healthcare
  • AliveCor Inc.

Table of Contents

1. Introduction

2. Research & Methodology

  • 2.1 Data Source
    • 2.1.1 Primary Sources
    • 2.1.2 Secondary Sources
  • 2.2 Research Approach
    • 2.2.1 Top-Down Approach
    • 2.2.2 Bottom-Up Approach
  • 2.3 Forecast Projection Methodology

3. Executive Summary

4. Market Dynamics

  • 4.1 Growth Drivers
  • 4.2 Challenges

5. United States Artificial Intelligence In Diagnostics Market

  • 5.1 Historical Market Trends
  • 5.2 Market Forecast

6. Market Share Analysis

  • 6.1 By Component
  • 6.2 By Application
  • 6.3 By End Use
  • 6.4 By States

7. Component

  • 7.1 Software
    • 7.1.1 Market Analysis
    • 7.1.2 Market Size & Forecast
  • 7.2 Services
    • 7.2.1 Market Analysis
    • 7.2.2 Market Size & Forecast
  • 7.3 Hardware
    • 7.3.1 Market Analysis
    • 7.3.2 Market Size & Forecast

8. Application

  • 8.1 Neurology
    • 8.1.1 Market Analysis
    • 8.1.2 Market Size & Forecast
  • 8.2 Radiology
    • 8.2.1 Market Analysis
    • 8.2.2 Market Size & Forecast
  • 8.3 Chest & Lung
    • 8.3.1 Market Analysis
    • 8.3.2 Market Size & Forecast
  • 8.4 Oncology
    • 8.4.1 Market Analysis
    • 8.4.2 Market Size & Forecast
  • 8.5 Cardiology
    • 8.5.1 Market Analysis
    • 8.5.2 Market Size & Forecast
  • 8.6 Pathology
    • 8.6.1 Market Analysis
    • 8.6.2 Market Size & Forecast
  • 8.7 Others
    • 8.7.1 Market Analysis
    • 8.7.2 Market Size & Forecast

9. End Use

  • 9.1 Hospitals & Clinics
    • 9.1.1 Market Analysis
    • 9.1.2 Market Size & Forecast
  • 9.2 Diagnostic Laboratories
    • 9.2.1 Market Analysis
    • 9.2.2 Market Size & Forecast
  • 9.3 Imaging Centers
    • 9.3.1 Market Analysis
    • 9.3.2 Market Size & Forecast
  • 9.4 Other End Users
    • 9.4.1 Market Analysis
    • 9.4.2 Market Size & Forecast

10. Top States

  • 10.1 California
    • 10.1.1 Market Analysis
    • 10.1.2 Market Size & Forecast
  • 10.2 Texas
    • 10.2.1 Market Analysis
    • 10.2.2 Market Size & Forecast
  • 10.3 New York
    • 10.3.1 Market Analysis
    • 10.3.2 Market Size & Forecast
  • 10.4 Florida
    • 10.4.1 Market Analysis
    • 10.4.2 Market Size & Forecast
  • 10.5 Illinois
    • 10.5.1 Market Analysis
    • 10.5.2 Market Size & Forecast
  • 10.6 Pennsylvania
    • 10.6.1 Market Analysis
    • 10.6.2 Market Size & Forecast
  • 10.7 Ohio
    • 10.7.1 Market Analysis
    • 10.7.2 Market Size & Forecast
  • 10.8 Georgia
    • 10.8.1 Market Analysis
    • 10.8.2 Market Size & Forecast
  • 10.9 New Jersey
    • 10.9.1 Market Analysis
    • 10.9.2 Market Size & Forecast
  • 10.10 Washington
    • 10.10.1 Market Analysis
    • 10.10.2 Market Size & Forecast
  • 10.11 North Carolina
    • 10.11.1 Market Analysis
    • 10.11.2 Market Size & Forecast
  • 10.12 Massachusetts
    • 10.12.1 Market Analysis
    • 10.12.2 Market Size & Forecast
  • 10.13 Virginia
    • 10.13.1 Market Analysis
    • 10.13.2 Market Size & Forecast
  • 10.14 Michigan
    • 10.14.1 Market Analysis
    • 10.14.2 Market Size & Forecast
  • 10.15 Maryland
    • 10.15.1 Market Analysis
    • 10.15.2 Market Size & Forecast
  • 10.16 Colorado
    • 10.16.1 Market Analysis
    • 10.16.2 Market Size & Forecast
  • 10.17 Tennessee
    • 10.17.1 Market Analysis
    • 10.17.2 Market Size & Forecast
  • 10.18 Indiana
    • 10.18.1 Market Analysis
    • 10.18.2 Market Size & Forecast
  • 10.19 Arizona
    • 10.19.1 Market Analysis
    • 10.19.2 Market Size & Forecast
  • 10.20 Minnesota
    • 10.20.1 Market Analysis
    • 10.20.2 Market Size & Forecast
  • 10.21 Wisconsin
    • 10.21.1 Market Analysis
    • 10.21.2 Market Size & Forecast
  • 10.22 Missouri
    • 10.22.1 Market Analysis
    • 10.22.2 Market Size & Forecast
  • 10.23 Connecticut
    • 10.23.1 Market Analysis
    • 10.23.2 Market Size & Forecast
  • 10.24 South Carolina
    • 10.24.1 Market Analysis
    • 10.24.2 Market Size & Forecast
  • 10.25 Oregon
    • 10.25.1 Market Analysis
    • 10.25.2 Market Size & Forecast
  • 10.26 Louisiana
    • 10.26.1 Market Analysis
    • 10.26.2 Market Size & Forecast
  • 10.27 Alabama
    • 10.27.1 Market Analysis
    • 10.27.2 Market Size & Forecast
  • 10.28 Kentucky
    • 10.28.1 Market Analysis
    • 10.28.2 Market Size & Forecast
  • 10.29 Rest of United States
    • 10.29.1 Market Analysis
    • 10.29.2 Market Size & Forecast

11. Value Chain Analysis

12. Porter's Five Forces Analysis

  • 12.1 Bargaining Power of Buyers
  • 12.2 Bargaining Power of Suppliers
  • 12.3 Degree of Competition
  • 12.4 Threat of New Entrants
  • 12.5 Threat of Substitutes

13. SWOT Analysis

  • 13.1 Strength
  • 13.2 Weakness
  • 13.3 Opportunity
  • 13.4 Threats

14. Pricing Benchmark Analysis

  • 14.1 Siemens Healthineers
  • 14.2 Riverain Technologies
  • 14.3 Vuno, Inc.
  • 14.4 Aidoc
  • 14.5 Neural Analytics
  • 14.6 Imagen Technologies
  • 14.7 GE Healthcare
  • 14.8 AliveCor Inc.

15. Key Players Analysis

  • 15.1 Siemens Healthineers
    • 15.1.1 Overviews
    • 15.1.2 Key Person
    • 15.1.3 Recent Developments
    • 15.1.4 SWOT Analysis
    • 15.1.5 Revenue Analysis
  • 15.2 Riverain Technologies
    • 15.2.1 Overviews
    • 15.2.2 Key Person
    • 15.2.3 Recent Developments
    • 15.2.4 SWOT Analysis
    • 15.2.5 Revenue Analysis
  • 15.3 Vuno, Inc.
    • 15.3.1 Overviews
    • 15.3.2 Key Person
    • 15.3.3 Recent Developments
    • 15.3.4 SWOT Analysis
    • 15.3.5 Revenue Analysis
  • 15.4 Aidoc
    • 15.4.1 Overviews
    • 15.4.2 Key Person
    • 15.4.3 Recent Developments
    • 15.4.4 SWOT Analysis
    • 15.4.5 Revenue Analysis
  • 15.5 Neural Analytics
    • 15.5.1 Overviews
    • 15.5.2 Key Person
    • 15.5.3 Recent Developments
    • 15.5.4 SWOT Analysis
    • 15.5.5 Revenue Analysis
  • 15.6 Imagen Technologies
    • 15.6.1 Overviews
    • 15.6.2 Key Person
    • 15.6.3 Recent Developments
    • 15.6.4 SWOT Analysis
    • 15.6.5 Revenue Analysis
  • 15.7 GE Healthcare
    • 15.7.1 Overviews
    • 15.7.2 Key Person
    • 15.7.3 Recent Developments
    • 15.7.4 SWOT Analysis
    • 15.7.5 Revenue Analysis
  • 15.8 AliveCor Inc.
    • 15.8.1 Overviews
    • 15.8.2 Key Person
    • 15.8.3 Recent Developments
    • 15.8.4 SWOT Analysis
    • 15.8.5 Revenue Analysis
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!